Cardiovascular Disease Risk: Screening With Electrocardiography

1. Studies that assess the incremental value of adding ECG to current CVD risk assessment tools or instruments to directly inform decision making and that examine patient outcomes.
2. Studies that assess the added value of ECG for risk reclassification across clinically relevant risk thresholds.
3. Studies of CVD risk assessment that evaluate the harms associated with assessment as well as those related to additional testing and treatment.
4. Studies measuring risk reclassification that report total, event, and nonevent Net Reclassification Indices, with corresponding confidence intervals and measures of calibration and discrimination.

The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening with resting or exercise ECG to prevent CVD events in asymptomatic adults at intermediate or high risk for CVD events.

Cardiovascular Disease Risk: Screening With Electrocardiography Read full statement 1